Antiresorptive drugs (bisphosphonates), atypical fractures and rebound effect: new evidence of similitude

Background: Homeopathy is based on treatment by similitude (‘like cures like’) administering to sick individuals substances that cause similar symptoms in healthy individuals, employing the secondary and paradoxical action of the organism as therapeutic response. This vital or homeostatic reaction of the organism can be scientifically explained by the rebound effect of drugs, resulting in worsening of symptoms after suspension of treatment. Bisphosphonates (BPs) reduce ‘typical’ fractures in patients with osteoporosis, but recent studies report ‘atypical’ fractures of the femur after stopping the BPs, a rebound effect may be the causal mechanism.

Method: Review of the literature concerning the relationship between atypical femoral fractures and antiresorptive drugs (bisphosphonates), identifying the pathogenesis of this adverse event.

Results: Several studies have described multiple cases of ‘atypical’ low-impact subtrochanteric stress fractures or complete fractures of the femur. These fractures are often bilateral, preceded by pain in the affected thigh, may have a typical X-ray appearance, and may delayed healing. Rebound of osteoclastic activity after suspension of antiresorptive drugs is a plausible mechanism to explain this phenomenon.

Conclusion: As for other classes of drugs, the rebound effect of antiresorptive drugs supports Hahnemann's similitude principle (primary action of the drugs followed by secondary and opposite action of the organism), and clarifies this ‘unresolved’ issue. Unfortunately, the rebound effect is little discussed among health professionals, depriving them of important knowledge ensure safe management of drugs.

Keywords

Homeopathy - Osteoporosis - Bisphosphonates - Fracture - Atypical - Law of similars - Secondary effect - Rebound effect - Paradoxical reaction

• References

• 1 Teixeira M.Z. New homeopathic medicines: use of modern drugs according to the principle of similitude. Homeopathy 2011; 100 (04) 244-252.
• 2 Hahnemann S. Organon of medicine. (Translated by William Boericke). 6th edn. New Delhi: B Jain Publishers; 1991.
• 3 Teixeira M.Z. Semelhante cura semelhante: o princípio de cura homeopático fundamentado pela racionalidade médica e científica. Similar cures similar: the homeopathic cure principle based by the medical and scientific rationality. São Paulo: Editorial Petrus; 1998.
• 4 Teixeira M.Z. Similitude in modern pharmacology. Homeopathy 1999; 88 (03) 112-120.
• 5 Teixeira M.Z. Evidence of the principle of similitude in modern fatal iatrogenic events. Homeopathy 2006; 95 (04) 229-236.
• 6 Teixeira M.Z. NSAIDs, myocardial infarction, rebound effect and similitude. Homeopathy 2007; 96 (01) 67-68.
• 7 Teixeira M.Z. Bronchodilators, fatal asthma, rebound effect and similitude. Homeopathy 2007; 96 (02) 135-137.
• 8 Teixeira M.Z. Antidepressants, suicidality and rebound effect: evidence of similitude?. Homeopathy 2009; 98 (01) 114-121.
• 9 Teixeira M.Z. Statins withdrawal, vascular complications, rebound effect and similitude. Homeopathy 2010; 99 (04) 255-262.
• 10 Teixeira M.Z. Rebound acid hypersecretion after withdrawal of gastric acid suppressing drugs: new evidence of similitude. Homeopathy 2011; 100 (03) 148-156.
• 11 Ioannidis G., Papaioannou A., Hopman W.M. et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 2009; 181 (05) 265-271.
• 12 Papaioannou A., Kennedy C.C., Ioannidis G. CaMos Study Group. et al. The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 2009; 20 (05) 703-714.
• 13 Haentjens P., Magaziner J., Colon-Emeric C.S. et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152 (06) 380-390.
• 14 Haleem S., Lutchman L., Mayahi R., Grice J.E., Parker M.J. Mortality following hip fracture: trends and geographical variations over the last 40 years. Injury 2008; 39 (10) 1157-1163.
• 15 Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83 (09) 1032-1045.
• 16 Wells G., Cranney A., Peterson J. et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008 (01): CD004523.
• 17 Wells G.A., Cranney A., Peterson J. et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008 (01): CD001155.
• 18 Wells G.A., Cranney A., Peterson J. et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008 (01): CD003376.
• 19 Cosman F. Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates. Endocr Pract 2009; 15 (05) 483-493.
• 20 Russell R.G.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19 (06) 733-759.
• 21 Cremers S.C., Pillai G., Papapoulos S.E. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005; 44 (06) 551-570.
• 22 Black D.M., Schwartz A.V., Ensrud K.E. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296 (24) 2927-2938.
• 23 Watts N.B., Diab D.L. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010; 95 (04) 1555-1565.
• 24 Zhang J., Saag K.G., Curtis J.R. Long-term safety concerns of antiresorptive therapy. Rheum Dis Clin North Am 2011; 37 (03) 387-400.
• 25 Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22 (05) 346-350.
• 26 Shane E., Burr D., Ebeling P.R. American Society for Bone and Mineral Research. et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25 (11) 2267-2294.
• 27 Salminen S., Pihlajamäki H., Avikainen V., Kyrö A., Böstman O. Specific features associated with femoral shaft fractures caused by low-energy trauma. J Trauma 1997; 43 (01) 117-122.
• 28 Nieves J.W., Bilezikian J.P., lane J.M. et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010; 21 (03) 399-408.
• 29 Wang Z., Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res 2011; 26 (03) 553-560.
• 30 Kelly M.P., Wustrack R., Bauer D.C. et al. Incidence of subtrochanteric and diaphyseal fractures in older white women: data from the study of osteoporotic fractures. 2010. ASBMR 2010 Annual Meeting. Toronto, Canada. Available at: http://www.asbmr.org/Itinerary/PresentationDetail.aspx?id=8feef0a5-2820-4c76-badc-4360fa2ace88 [accessed 01.03.12].
• 31 Ekstrom W., Nemeth G., Samnegard E., Dalen N., Tidermark J. Quality of life after a subtrochanteric fracture: a prospective cohort study on 87 elderly patients. Injury 2009; 40 (04) 371-376.
• 32 US Food and Drug Administration ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures. FDA Drug Safety Communication; 2010. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm204127.htm [accessed 01.03.12].
• 33 Schneider J.P. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 2009; 64 (01) 18-23.
• 34 Agarwal S., Agarwal S., Gupta P., Agarwal P.K., Agarwal G., Bansal A. Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates): a systemic review of literature. Acta Orthop Belg 2010; 76 (05) 567-571.
• 35 Nieves J.W., Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep 2010; 8 (01) 34-39.
• 36 Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010; 47 (02) 169-180.
• 37 Boonen S., Ferrari S., Miller P.D. et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective. J Bone Miner Res 2012; 27 (05) 963-974.
• 38 Schneider J.P. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006; 61 (01) 31-33.
• 39 Cheung R.K., Leung K.K., Lee K.C., Chow T.C. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 2007; 13 (06) 485-489.
• 40 Kumm D.A., Rack C., Rutt J. Subtrochanteric stress fracture of the femur following total knee arthroplasty. J Arthroplasty 1997; 12 (05) 580-583.
• 41 Demiralp B., Ilgan S., Ozgur Karacalioglu A. et al. Bilateral femoral insufficiency fractures treated with inflatable intramedullary nails: a case report. Arch Orthop Trauma Surg 2007; 127 (07) 597-601.
• 42 Somford M.P., Draijer F.W., Thomassen B.J., Chavassieux P.M., Boivin G., Papapoulos S.E. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009; 24 (10) 1736-1740.
• 43 Husada G., Libberecht K., Peeters T., Populaire J. Bilateral mid-diaphyseal femoral stress fractures in the elderly. Eur J Trauma 2005; 31 (01) 68-71.
• 44 Sayed-Noor A.S., Sjoden G.O. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res 2009; 467 (07) 1921-1926.
• 45 Odvina C.V., Zerwekh J.E., Rao D.S. et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90 (03) 1294-1301.
• 46 Visekruna M., Wilson D., McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008; 93 (08) 2948-2952.
• 47 Girgis C.M., Sher D., Seibel M.J. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010; 362 (19) 1848-1849.
• 48 Papapoulos S.E. Bisphosphonates for postmenopausal osteoporosis. In: Rosen C.J. (ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 7th edn. 2008. Washington, DC: American Society for Bone and Mineral Research; p. 237–241.
• 49 Papapoulos S.E. Bisphosphonates: how do they work?. Best Pract Res Clin Endocrinol Metab 2008; 22 (05) 831-847.
• 50 Lenart B.A., Neviaser A.S., Lyman S. et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009; 20 (08) 1353-1362.
• 51 Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register based national cohort study. J Bone Miner Res 2009; 24 (06) 1095-1102.
• 52 Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients during long-term alendronate therapy: expanded and extended national register-based cohort study 37th European Symposium on Calcified Tissues (ECTS 2010). 2010. Glasgow, Scotland, United Kingdom.
• 53 Vestergaard P., Amtssygehus A. Risk of femoral shaft and subtrochanteric fractures in users of bisphophonates, raloxifene and strontium ranelate. ASBMR 2010 Annual Meeting 2010. Toronto, Canada.
• 54 Black D.M., Kelly M.P., Genant H.K. et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362 (19) 1761-1771.
• 55 Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N. et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305 (08) 783-789.
• 56 Abrahamsen B., Eiken P., Eastell R. Cumulative alendronate dose and the long-term absolute aisk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010; 95 (12) 5258-5265.
• 57 Schilcher J., Michaelsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364 (18) 1728-1737.
• 58 Li J., Mashiba T., Burr D.B. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001; 69 (05) 281-286.
• 59 Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces biomechanical properties in dog rib. J Bone Miner Res 2000; 15 (04) 613-620.
• 60 Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28 (05) 524-531.
• 61 Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation?. Bone 2000; 27 (01) 13-20.
• 62 Boivin G., Meunier P.J. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res 2002; 43 (02/03) 535-537.
• 63 Akkus O., Polyakova-Akkus A., Adar F., Schaffler M.B. Aging and microstructural compartments in human compact bone. J Bone Miner Res 2003; 18 (06) 1012-1019.
• 64 Ciarella T.E., Fyhrie D.P., Parfitt A.M. Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 2003; 32 (03) 311-315.
• 65 Kitano M., Ogata A., Sekiguchi M., Hamano T., Sano H. Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease. J Bone Miner Metab 2005; 23 (01) 48-52.
• 66 Rosen H.N., Moses A.C., Garber J. et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000; 66 (02) 100-103.
• 67 Fujikawa Y., Quinn J.M., Sabokbar A., McGee J.O., Athanasou N.A. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996; 137 (09) 4058-4060.
• 68 Hernandez C.J. How can bone turnover modify bone strength independent of bone mass?. Bone 2008; 42 (06) 1014-1020.
• 69 Brown J.E., Cook R.J., Major P. et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. JNCI 2005; 97 (01) 59-69.
• 70 Heiss G., Wallace R., Anderson G.L. et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299 (09) 1036-1045.
• 71 Yates J., Barrett-Connor E., Barlas S., Chen Y.T., Miller P.D., Siris E.S. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004; 103 (03) 440-446.
• 72 Gallagher J.C., Rapuri P.B., Haynatzki G., Detter J.R. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 2002; 87 (11) 4914-4923.
• 73 Christiansen C., Christensen M.S., Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; 1 (8218): 459-461.
• 74 Greenspan S.L., Emkey R.D., Bone H.G. et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137 (11) 875-883.
• 75 Miller P.D., Bolognese M.A., Lewiecki E.M. Amg Bone Loss Study Group. et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43 (02) 222-229.
• 76 Cummings S.R., San Martin J., McClung M.R. FREEDOM Trial. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361 (08) 756-765.
• 77 Papapoulos S., Bone H., Brandi M.L. et al. Four years of denosumab exposure in women with postmenopausal osteoporosis: results from the first year extension of the FREEDOM trial. J Bone Miner Res 2010; 25 (Suppl. 01) S1-S81.
• 78 Miller P.D., Wagman R.B., Peacock M. et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 2011; 96 (02) 394-402.
• 79 Bone H.G., Bolognese M.A., Yuen C.K. et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96 (04) 972-980.
• 80 Eisman J.A., Bone H.G., Hosking D.J. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011; 26 (02) 242-251.
• 81 World Health Organization (WHO). The importance of pharmacovigilance. Safety Monitoring of Medicinal Products. 2002. The Uppsala Monitoring Centre.;
• 82 Webster's new World medical dictionary. 3rd edn. New Jersey: Wiley Publishing; 2008.
• 83 Hodding G.C., Jann M., Ackerman I.P. Drug withdrawal syndromes – a literature review. West J Med 1980; 133 (05) 383-391.
• 84 Wolfe R.M. Antidepressant withdrawal reactions. Am Fam Physician 1997; 56 (02) 455-462.
• 85 Oniani T.N., Akhvlediani G.R. Influence of some monoamine oxidase inhibitors on the sleep-wakefulness cycle of the cat. Neurosci Behav Physiol 1988; 18 (04) 301-306.
• 86 Reidenberg M.M. Drug discontinuation effects are part of the pharmacology of a drug. J Pharmacol Exp Ther 2011; 339 (02) 324-328.
• 87 Zoehrer R., Roschger P., Paschalis E.P. et al. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res 2006; 21 (07) 1106-1112.
• 88 Boivin G., Bala Y., Chapurlat R.D., Delmas P.D. Long-term treatment with oral bisphosphonates in postmenopausal women: effects on the degree of mineralization and microhardness of bone. J Bone Miner Res 2008; 23 (Suppl. 01) S10.
• 89 Roschger P., Lombardi A., Misof B.M. et al. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the Fracture Intervention Trial Long-term Extension (FLEX). J Bone Miner Res 2010; 25 (01) 48-55.
• 90 Chavassieux P.M., Arlot M.E., Roux J.P. et al. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000; 15 (04) 754-762.
• 91 Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100 (06) 1475-1480.
• 92 Eriksen E.F., Melsen F., Sod E., Barton I., Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002; 31 (05) 620-625.
• 93 Allen M.R., Burr D.B. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67 (Suppl. 05) 61-70.
• 94 Brozoski M.A., Traina A.A., Deboni M.C., Marques M.M., Naclério-Homem Mda G. Bisphosphonate-related osteonecrosis of the jaw. Rev Bras Reumatol 2012; 52 (02) 265-270.
• 95 Whitaker M., Guo J., Kehoe T., Benson G. Bisphosphonates for osteoporosis – where do we go from here?. N Engl J Med 2012; 366 (22) 2048-2051.
• 96 Schuiling K.D., Robinia K., Nye R. Osteoporosis update. J Midwifery Womens Health 2011; 56 (06) 615-627.
• 97 Gibson M.V. Evaluation and treatment of bone disease after fragility fracture. Geriatrics 2008; 63 (07) 21-30.
• 98 Goh S.K., Yang K.Y., Koh J.S. et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89 (03) 349-353.
• 99 Rizzoli R., Akesson K., Bouxsein M. et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011; 22 (02) 373-390.
• 100 National Institute for Health and Clinical Excellence. Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended). 2010. NICE Technology appraisal guidance 160 (amended). Available at: http://www.nice.org.uk/nicemedia/pdf/TA160guidance.pdf [accessed 01.03.12].
• 101 Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17 (12) 1726-1733.
• 102 Rodríguez L.A., Cea-Soriano L., Martín-Merino E., Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case–control study in UK primary care. BMJ 2011; 343: d4094.
• 103 García Rodríguez L.A., Cea Soriano L., Hill C., Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology 2011; 76 (08) 740-746.
• 104 Teixeira M.Z. Rebound effect of drugs: fatal risk of conventional treatment and pharmacological basis of homeopathic treatment. Int J High Dilution Res 2012; 11 (39) 69-106.
• 105 Teixeira M.Z. São Paulo: Marcus Zulian Teixeira; New homeopathic medicines: use of modern drugs according to the principle of similitude. vol. 3. 2010. Available at: http://www.newhomeopathicmedicines.com.